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The major histocompatibility complex (MHC) class I chain-related A (MICA) is the most 
polymorphic non-classical MHC class I gene in humans. It encodes a ligand for NKG2D 
(NK group 2, member D), an activating natural killer (NK) receptor that is expressed 
mainly on NK cells and CD8+ T cells. The single-nucleotide polymorphism (SNP) 
rs1051792 causing a valine (Val) to methionine (Met) exchange at position 129 of the 
MICA protein is of specific interest. It separates MICA into isoforms that bind NKG2D 
with high (Met) and low affinities (Val). Therefore, this SNP has been investigated for 
associations with infections, autoimmune diseases, and cancer. Here, we systematically 
review these studies and analyze them in view of new data on the functional conse-
quences of this polymorphism. It has been shown recently that the MICA-129Met variant 
elicits a stronger NKG2D signaling, resulting in more degranulation and IFN-γ production 
in NK cells and in a faster costimulation of CD8+ T cells than the MICA-129Val variant. 
However, the MICA-129Met isoform also downregulates NKG2D more efficiently than 
the MICA-129Val isoform. This downregulation impairs NKG2D-mediated functions at 
high expression intensities of the MICA-Met variant. These features of the MICA-129Met/
Val dimorphism need to be considered when interpreting disease association studies. 
Particularly, in the field of hematopoietic stem cell transplantation, they help to explain the 
associations of the SNP with outcome including graft-versus-host disease and relapse 
of malignancy. Implications for future disease association studies of the MICA-129Met/
Val dimorphism are discussed.
Keywords: nK cells, T cells, activating nK receptor, costimulation, single-nucleotide polymorphism, autoimmune 
diseases, cancer, hematopoietic stem cell transplantation
inTRODUCTiOn
The major histocompatibility complex (MHC) class I chain-related A (MICA) is the most polymor-
phic non-classical MHC class I gene in humans, and 105 alleles are known encoding for 82 protein 
variants (http://www.ebi.ac.uk/imgt/hla/, release 3.25.0). MICA is encoded within the human 
leukocyte antigen (HLA) complex close to HLA-B (1, 2). The protein structure is similar to classical 
class I molecules, but MICA is not associated with β2-microglobulin and does not present peptides. 
MICA is constitutively expressed only on a few cell types, including gastrointestinal epithelium, but 
is induced due to cellular and genotoxic stress (3, 4), malignant transformation, or virus infection 
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(5, 6). MICA is a ligand for NKG2D (NK group 2, member D), 
an activating natural killer (NK) receptor encoded by the KLRK1 
gene (7). NKG2D is expressed on most human NK cells, CD8+ αβ 
T cells, γδ T cells, iNKT cells, and subsets of effector or memory 
CD4+ T cells (8, 9). On NK cells, NKG2D signaling elicits kill-
ing of target cells (10) and secretion of IFN-γ (11). On CD8+ 
αβ T cells, NKG2D provides a costimulatory signal to activate 
naïve cytotoxic T lymphocytes (12). NKG2D contributes to the 
elimination of tumor cells (13) and plays a role in the defense 
against pathogens (14, 15). In addition to MICA, MICB and the 
UL16-binding proteins (ULBP) encoded by the retinoic acid early 
transcript 1 (RAET1) family function as ligands for NKG2D. 
MICB is also very polymorphic with 42 alleles encoding 28 
protein variants (http://www.ebi.ac.uk/imgt/hla/, release 3.25.0). 
The RAET1 gene family is localized on chromosome 6 outside 
the HLA complex and six loci encode functional proteins (16). 
RAET1 genes are less polymorphic than MICA and MICB.
Polymorphisms of MICA have been investigated for their role 
in infections, autoimmune diseases, and cancer (17–21). The 
single-nucleotide polymorphism (SNP) rs1051792 (G/A) causing 
a valine (Val) to methionine (Met) exchange at position 129 in 
the α2 domain of the MICA protein has gained specific interest. 
It separates MICA alleles into two groups (22). MICA isoforms 
containing a methionine at position 129 bind NKG2D with high 
affinity, whereas those with a valine bind NKG2D with low affin-
ity. High-affinity alleles include MICA*001, *002, *007, and *017; 
among the low-affinity alleles are MICA*004, *006, *008, *009, 
and *010 (23). Due to its functional consequences, the MICA-
129Met/Val dimorphism has been investigated in several disease 
association studies. Here, we review these studies in view of new 
data on the functional consequences of this amino acid variation 
elicited after binding to NKG2D.
MiCA-129Met/val DiSeASe  
ASSOCiATiOn STUDieS
In September 2016, we searched Pubmed for MICA-129Met/
Val disease association studies using the key words rs1051792, 
MICA-129, MICA AND polymorphism AND Met, and MICA 
AND polymorphism AND Val. Moreover, we exchanged 
polymorphism by SNP, Met by methionine, and Val by valine. 
We identified 17 publications, in which an association of the 
MICA-129Met/Val dimorphism with a disease or disease com-
plication has been investigated. One study in Chinese language 
(24) appeared to be not independent of a larger study published in 
English (25). Thus, we analyzed 16 independent studies published 
between 2005 and 2015 (Table S1 in Supplementary Material). 
Three studies are small with less than 100 cases. All others are of 
a medium size with more than 100 but less than 1,000 patients 
included, and most studies used a case–control design.
Eight studies investigated associations with autoimmune dis-
eases, i.e., ankylosing spondylitis (AS) (26), rheumatoid arthritis 
(RA) (27–29), inflammatory bowel disease (IBD) (25, 30) [includ-
ing ulcerative colitis (UC) and Crohn’s disease], systemic lupus 
erythematosus (SLE) (28), type I diabetes (31), latent autoimmune 
diabetes in adults (LADA) (31), and psoriasis (32). In one study, 
the MICA-129 SNP has not been determined directly. Instead, the 
SNP rs1051794 was typed and reported to be in complete linkage 
disequilibrium with the rs1051792 (27). Five studies reported on 
malignancies, i.e., nasopharyngeal cancer (33), hepatitis B virus 
(HBV)-induced hepatocellular carcinoma (HCC) (34), cutane-
ous malignant melanoma (35), and relapse of malignancy after 
hematopoietic stem cell transplantation (HSCT) (36, 37). Three 
studies investigated infections or their complications, i.e., HBV 
infection and HBV-induced HCC (34), left ventricular systolic 
dysfunction (LVSD) in chronic Chargas heart disease (38), and 
ocular toxoplasmosis (39). One study investigated an association 
of the MICA-129Met/Val dimorphism with recurrent miscar-
riage (40). The two studies on HSCT (36, 37) investigated besides 
relapse also other outcomes including graft-versus-host disease 
(GVHD).
Three studies, on recurrent miscarriage (40), ocular toxoplas-
mosis (39), and malignant melanoma (35), failed to demonstrate 
an association with the SNP. Thus, 81% of the studies showed an 
association at least for a subgroup, e.g., juvenile AS, whereas in 
all patients with AS, the association was dependent on HLA-B27 
(26), or a sub-phenotype, e.g., severe LVSD (38). However, we 
must assume that other negative association studies have not 
been published. In seven studies, a MICA-129 allele and the cor-
responding homozygous genotype were both associated with a 
disease risk (25, 28, 29, 31, 32, 34, 38). The odds ratio (OR) was 
then always higher for the genotype than the allele. In six studies, 
the Met  allele and/or the Met/Met genotype were found to be 
associated with a risk, including autoimmune diseases [juvenile 
AS (26), UC (30), SLE (28), and psoriasis (32)], a malignancy 
(HBV-induced HCC) (34), and a complication of an infection 
(severe LVSD in chronic Chargas disease) (38). In three studies, 
the Val allele and/or the Val/Val genotype has been identified 
to confer a risk for autoimmune diseases [including RA (27), 
UC (25), and diabetes (31)] and for nasopharyngeal carcinoma 
(NPC) (33). Moreover, rheumatoid factor (RF) positivity in 
RA patients has been associated with the Val allele and the Val/
Val genotype (29). In the studies on HSCT, different outcomes 
showed different associations. In one study (36), the Met/Met 
genotype was associated with an increased risk of relapse and the 
Val/Val genotype with an increased risk of chronic GVHD. In our 
recent study (37), the Met/Met genotype conferred a risk of acute 
GVHD, whereas having Met alleles reduced the risk to die from 
acute GVHD. Overall, the Val allele was associated with a higher 
mortality after HSCT (37).
The results of these disease association studies do not allow 
for a simple unifying interpretation, such as the high-affinity 
MICA-129Met variant being associated with an activation 
of the immune system resulting in a lower risk of infections 
and cancer but higher risk of autoimmunity (Figures  1A,B). 
Autoimmune diseases are associated with both variants even 
within the same disease entity. UC, e.g., has been associated 
with the Met/Met genotype in a small study from Spain (30) but 
with the Val allele and Val/Val genotype in a larger study from 
China (25). RA has been associated with the Val allele in a study 
from France and Germany (27), but no association was found 
in cohorts from Japan (28) and Tunisia (29). Notably, a role of 
the NKG2D pathway has been reported for the pathogenesis 
of RA (41) and SLE (42), although this has not been linked to 
FiGURe 1 | Reported associations of the homozygous MICA-129 genotypes (A) and the MICA-129 alleles (B) with health risks [odds ratio (OR) > 1] or 
advantages (OR < 1). Shown are ORs with 95% confidence intervals (CI) or hazard ratios reported by Boukouaci et al. (36) and Isernhagen et al. (37) (overall 
survival) in event-time data. The number of patients analyzed in the studies is indicated at the y-axis. Studies reporting on autoimmune diseases are shown by open 
and closed blue symbols and malignancies by red symbols; studies reporting complications of infections (LVSD, Chargas disease; HCC, hepatitis B virus infection) 
are shown by green frames, and others are displayed by black symbols. The investigated diseases or complications and the references for the studies are indicated. 
(A) MICA-129Met/Met genotype effects are directly displayed. For studies that reported MICA-129Val/Val genotype effects [chronic GVHD (36), NPC (33), UC (25), 
RA (27), T1D, and LADA (31), indicated by brown font], the graph displays the corresponding effect of the pooled MICA-129 Met/Met and MICA-129Met/Val 
genotypes to allow for a direct comparison. (B) MICA-129Met allele effects are directly displayed. For studies that reported MICA-129Val allele effects [UC (25), T1D, 
and LADA (31), indicated by brown font], the graph displays the corresponding effect of the MICA-129Met allele; ORMet = 1/ORVal and 95%-CIMet = (1/CIVal, 
upper, 1/CIVal, lower). Abbreviations: CPs, cutaneous psoriasis; GVHD, graft-versus-host disease; HCC, hepatocellular carcinoma; JAS, juvenile ankylosing 
spondylitis; LADA, latent autoimmune diabetes in adults; LVSD, left ventricular systolic dysfunction; NPC, nasopharyngeal carcinoma; PsA, psoriatic arthritis; RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; T1D, type 1 diabetes; UC, ulcerative colitis.
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polymorphisms. Juvenile AS has been associated in a small 
study with the Met/Met genotype (26), and a larger sequencing 
study identified the MICA*007:01 allele that encodes a methio-
nine at position 129 as a risk allele for AS in both Caucasian and 
Han Chinese populations (43). However, MICA*019, encoding 
a valine-129, has been identified as the major risk allele in Han 
Chinese (43). Malignancies were found to be associated with 
Val/Val genotype in the case of NPC (33) but with the Met/Met 
genotype in the case of relapse after HSCT (36). These different 
associations could suggest that the observed associations are 
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random or dependent on the population studied. However, 
since the MICA-129Met/Val dimorphism is functional, it could 
also indicate that we need to better understand this function 
to predict its consequences in the pathophysiology of different 
diseases in various populations, which might be exposed to 
different interfering environmental factors. This assumption is 
supported by genome-wide association studies (GWAS), which 
have assigned disease risks for NPC (44), HCC (45, 46), cervical 
cancer (47, 48), and asthma (49) or advantages, such as HIV 
long-term non-progression (50) to the MICA gene region in an 
unbiased manner.
FUnCTiOnAL COnSeQUenCeS OF 
THe MiCA-129Met/val DiMORPHiSM
It has been shown by Steinle and colleagues that MICA-129Met 
isoforms bind NKG2D with high affinity in contrast to MICA-
129Val isoforms that bind with low affinity (22). Yoshida and 
colleagues combined the MICA-129Met variant with the A9 
variant of a microsatellite polymorphism in the transmembrane 
(TM) region and the MICA-129Val variant with the A5-TM 
variant in GST-fusion proteins (28). NK92MI cells showed 
a reduced NKG2D expression and killed K562 cells less effi-
ciently when exposed to the MICA-129Met-A9-TM variant, 
but IFN-γ production was increased (28). We recently studied 
the consequences of binding of the two MICA-129 variants 
to NKG2D on primary NK cells and CD8+ T cells using cell 
lines transfected with expression constructs and recombinant 
Fc-fusion proteins differing only in amino acid 129 (37, 51). 
The recombinant MICA-129Met variant stimulated a stronger 
phosphorylation of SRC family kinases in NK cells than the 
MICA-129Val variant. Subsequently, the MICA-129Met ligand 
triggered more degranulation and IFN-γ production than the 
MICA-129Val ligand (Figure 2A). We then exposed NK cells to 
target cells expressing different amounts of the MICA-129 vari-
ants. The extent of degranulation and IFN-γ secretion correlated 
positively with the MICA expression intensity on the target cells 
but only for the MICA-129Val isoform. The expression intensity 
of the MICA-129Met isoform, in contrast, had either none or 
even a negative effect on the extent of degranulation, target cell 
killing, and IFN-γ release (37). On CD8+ T cells, the MICA-
129Met isoform induced an earlier costimulatory activation 
than the MICA-129Val isoform (Figure  2B). Importantly, the 
MICA-129Met ligand induced also a stronger downregulation 
of NKG2D on both NK and CD8+ T cells than the MICA-129Val 
ligand. This downregulation of NKG2D impaired the capability 
of NK and CD8+ T cells to receive signals via NKG2D (37). Thus, 
MICA-129Met ligands, which elicit strong NKG2D responses, 
stimulate in parallel a robust negative feedback signal by down-
regulation of NKG2D that limits the initially stronger effects of 
MICA-129Met ligands. These data show that the biological effect 
of the MICA-129Met/Val dimorphism changes with the MICA 
expression intensity. Variant MICA-129Met triggers more 
NKG2D signals at low expression intensities, whereas variant 
MICA-129Val elicits more NKG2D effects at high expression, 
at which the MICA-129Met variant already downregulates 
NKG2D leading to impaired function. Thus, the biological effect 
of the SNP can hardly be predicted without information on the 
expression intensity of MICA.
It is known that expression intensities vary for certain MICA 
alleles (52, 53). The G allele of the SNP at -1878 (rs2596542) in 
the promoter region of the MICA gene region, e.g., was found 
to have a higher transcriptional activity (54). Biological effects 
of the MICA-129Met/Val dimorphism can be expected to be 
modified by polymorphisms affecting MICA gene expression. 
We have investigated whether the Met/Val dimorphism itself 
affects MICA expression. In transfected cells, more of the MICA-
129Met variant was retained in intracellular compartments 
(51). A similar alteration of the intracellular transport has been 
described for MICA-A5.1 variants (55). Thus, the combination 
of polymorphisms affecting transcription and intracellular 
transport of MICA could modify the effect of the Met/Val 
dimorphism.
Another important aspect of MICA is the generation of solu-
ble MICA (sMICA) by proteolytic shedding. sMICA can induce 
NKG2D downregulation (56, 57) resulting in tumor immune 
escape (58). Some MICA polymorphisms have been reported 
to affect the amounts of sMICA in sera of patients including 
the SNP at -1878 (rs2596542) in the promoter region (34, 45, 
59) that affects transcription (54), a microsatellite in exon 5 
encoding the TM region (60, 61), and the MICA-129Met/Val 
dimorphism. In patients with UC, the MICA-129Val/Val geno-
type was associated with higher sMICA serum levels (25), and 
the MICA-129Val allele was also associated with higher sMICA 
serum levels in HBV patients and controls (34). In transfected 
cells, we found that the MICA-129Met isoform was more suscep-
tible to shedding than the MICA-129Val isoform (51). However, 
due to the intracellular retention of the MICA-129Met variant 
(51), less sMICA might appear in sera (25, 34). Notably, intracel-
lular retention and preferred shedding both appear to limit the 
expression of the high-affinity MICA-129Met isoform at the 
plasma membrane.
MiCA-129Met/val DiSeASe 
ASSOCiATiOnS in view OF 
BiOLOGiCAL FUnCTiOnS
Recent data on the MICA-129Met/Val variation demonstrate 
the complexity of the functional consequences of this exchange 
of a single amino acid (37, 51). There are several layers of this 
complexity, which are as follows: (1) the function of the variant is 
not constant but dynamic (37); it depends on the MICA expres-
sion intensity, and the direction of the biological effect can invert 
for the MICA-129Met variant at higher expression. (2) Epistatic 
effects must be expected for this SNP as polymorphisms affecting 
the expression of MICA will modify the functional effects of the 
MICA-129Met/Val isoforms. Moreover, the expression intensity 
of NKG2D can be modified by SNPs in the KLRK1 gene (62) and 
those might interact with the MICA-129 variants. Other genes 
within the NKG2D pathway including other ligands might also 
show epistatic effects (63). (3) MICA can target NKG2D on 
several cell types, and biological effects on different cell types 
might be synergistic or antagonistic. An activation of NK cells 
and a costimulation of CD8+ T cells both can promote antitumor 
FiGURe 2 | Summary of functional effects of MiCA-129 variants depending on expression intensity. (A) For target cells expressing the MICA-129Val 
variant, the degree of natural killer (NK) cell cytotoxicity and IFN-γ production increases steadily with the MICA expression intensity. Augmented expression of the 
high-affinity MICA-129Met isoform, in contrast, has none or even a negative effect on these NK cell functions due to a rapid downregulation of NKG2D on NK 
cells. (B) Antigen-dependent costimulation of CD8+ T cells with the MICA-129Met variant allows for an earlier antigen-dependent activation than costimulation 
with the MICA-129Val variant. However, the downregulation of NKG2D in response to MICA-129Met ligands impairs any subsequent NKG2D-dependent 
costimulation and T cell activation. The downregulation of NKG2D on CD8+ T cells is augmented with MICA-129Met expression intensity. The figure is reproduced 
from Isernhagen et al. (37).
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immunity. By contrast, a strong activation of NK cells might 
polarize an immune response to a Th1 reaction and reduce the risk 
to develop a Th2-mediated autoimmune disease. (4) Additional 
factors, such as sMICA or anti-MICA antibodies (36) that might 
neutralize sMICA, have been shown to be functionally important 
and have been determined in some of the disease association 
studies (25, 34, 36).
Currently, we mostly have not sufficient clinical and biological 
information to interpret the MICA-129Met/Val disease associa-
tion studies in view of the complex function of this polymorphism. 
However, the two HSCT studies do provide more information 
and illustrate the clinical effects of the MICA-129Met/Val dimor-
phism as explained previously in detail (37). In our study (37), 
the homozygous carriers of Met alleles had an increased risk to 
experience acute GVHD, possibly due to immediate strong effects 
of MICA-129Met variants on NKG2D signaling. Having at least 
one Met allele reduced the risk to die from acute GVHD likely due 
to a rapid downregulation of NKG2D on alloreactive CD8+ T cells 
mediated by engagement of a high-affinity MICA-129Met vari-
ant. Carrying a MICA-129Met allele increased in consequence the 
chance of survival in all patients and in patients receiving a MICA-
129-matched graft (37). Boukouaci and colleagues reported an 
increased risk of chronic GVHD for recipients with the Val/Val 
genotype, whereas the Met/Met genotype was associated with the 
risk of relapse (36). Sustained NKG2D-mediated activation of 
alloreactive CD8+ T cells would be expected if only MICA-129Val 
variants are present that fail to efficiently downregulate NKG2D, 
and this could increase the risk of chronic GVHD but reduce 
the risk of relapse. Thus, the different risk associations reported 
in the two studies are not arguing against the relevance of the 
MICA-129 dimorphism for the outcome of HSCT. The principal 
relevance of the NKG2D pathway for HSCT is further emphasized 
by studies showing an effect of the genotype of the NKG2D ligand 
RAET1L (64) and NKG2D itself (65) on the survival of patients. 
Moreover, matching for MICA alleles (66–69) and specifically 
for the MICA-129 polymorphism (70) is beneficial in HSCT. The 
huge effect of MICA-129 matching appears hardly explainable 
solely by the avoidance of a potential minor histocompatibility 
antigen. A “tuning” of the threshold of NKG2D signaling toward 
the affinity of NKG2D ligands present in an individual (52) and 
disturbance of this balance by mismatching could be considered 
as an alternative explanation.
Despite the functional relevance of the MICA-129 SNP, it 
cannot be excluded that some of the associations reported are 
random or caused by linkage disequilibrium with classical HLA 
genes. The association of MICA-129 with psoriasis (32) has been 
disproven in large GWAS cohorts (71). However, associations 
with NPC (33) and HCC (34) are supported by GWAS data point-
ing to the MICA gene region (44–46).
COnCLUSiOn
Information on functional consequences of a polymorphism is 
indispensable for understanding disease associations. The varia-
tion in the disease associated allele or genotype of MICA-129 in 
the published studies must not indicate random associations. For 
MICA-129, the biological function can change with expression 
intensity, epistatic interactions can be expected, the effect on 
different lymphocytes can vary, and modifying factors, such as 
sMICA, have to be considered. Notably, as expected for a func-
tional SNP with a minor allele (MICA-129Met) frequency rang-
ing from 48% in Africans to 30% in Asians (72), and being even 
the major allele reported in one of the analyzed studies (26), both 
alleles appear to confer advantages and disadvantages in specific 
situations suggesting balancing evolution of the MICA alleles. 
Since the MICA-129 dimorphism is considered as decisive for 
distinguishing low- and high-affinity variants (22), the frequency 
of alleles encoding high-affinity MICA variants is expected to 
match the frequency of the MICA-129Met variant. However, 
other MICA polymorphisms and their interaction need to be 
studied further (73).
In future studies, the MICA-129Met/Val dimorphism should 
be analyzed in larger cohorts. Detailed clinical information would 
help to understand why associations might differ in cohorts. 
Additional biological information should be obtained in parallel 
to genetic data. Most important would be data on MICA expres-
sion intensities in relevant tissues at relevant time points. Due to 
the complexity of MICA-129Met/Val effects, this polymorphism 
is unlikely to become a simple genetic biomarker for prediction 
of disease risks. However, it still may provide highly important 
information. We found that Val/Val genotype carriers undergoing 
HSCT specifically profited from a treatment with antithymocyte 
globulin to deplete T cells (37). This might be explained by a lack 
of a high-affinity MICA variant that efficiently downregulates 
NKG2D on alloreactive donor CD8+ T cells. Moreover, the MICA-
129 dimorphism might be relevant when considering therapies 
aiming at upregulation of MICA on tumor cells to sensitize them 
for NK cells (74, 75). Increasing the expression of MICA-129Met 
variants could result in opposite effects than intended.
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